SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla jumps on reporting 58.19% surge in Q1 net profit

01 Aug 2012 Evaluate

Cipla is currently trading at Rs. 361.20, up by 22.65 points or 6.69% from its previous closing of Rs. 338.55 on the BSE.

The scrip opened at Rs. 360.00 and has touched a high and low of Rs. 363.60 and Rs. 356.20 respectively. So far 2,70,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 363.60 on 01-Aug-2012 and a 52 week low of Rs. 273.60 on 06-Sep-2011.

Last one week high and low of the scrip stood at Rs. 363.60 and Rs. 325.25 respectively. The current market cap of the company is Rs. 29,001.00 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.23% and 28.73% respectively.

On standalone basis, the company has reported a surge of 58.19% in its net profit at Rs 400.76 crore for the quarter, as compared to Rs 253.34 crore for the same quarter in the previous year.  Total income of the company has increased by 23.85% to Rs 2011.25 crore for the quarter under review as compared to Rs 1623.98 crore for the quarter ended June 30, 2011.

Cipla manufactures drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions. Its products are distributed in more than 180 countries worldwide. The Mumbai-based firm which enjoys the highest share in India's pharmaceuticals market is known for selling low-cost generic versions of anti-retroviral drugs used to fight HIV/AIDS.

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×